103 related articles for article (PubMed ID: 36365185)
1. Mechanistic Modeling of Placental Drug Transfer in Humans: How Do Differences in Maternal/Fetal Fraction of Unbound Drug and Placental Influx/Efflux Transfer Rates Affect Fetal Pharmacokinetics?
Liu XI; Green DJ; van den Anker JN; Rakhmanina NY; Ahmadzia HK; Momper JD; Park K; Burckart GJ; Dallmann A
Front Pediatr; 2021; 9():723006. PubMed ID: 34733804
[No Abstract] [Full Text] [Related]
2. Optimization of the betamethasone and dexamethasone dosing regimen during pregnancy: a combined placenta perfusion and pregnancy physiologically based pharmacokinetic modeling approach.
Van Der Heijden JEM; Van Hove H; Van Elst NM; Van Den Broek P; Van Drongelen J; Scheepers HCJ; De Wildt SN; Greupink R
Am J Obstet Gynecol; 2024 May; ():. PubMed ID: 38763343
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic Coupling of a Novel
Mian P; Nolan B; van den Anker JN; van Calsteren K; Allegaert K; Lakhi N; Dallmann A
Front Pediatr; 2021; 9():733520. PubMed ID: 34631628
[TBL] [Abstract][Full Text] [Related]
4. An Application of a Physiologically Based Pharmacokinetic Approach to Predict Ceftazidime Pharmacokinetics in a Pregnant Population.
Abduljalil K; Gardner I; Jamei M
Pharmaceutics; 2024 Mar; 16(4):. PubMed ID: 38675135
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic Framework to Predict Maternal-Placental-Fetal Pharmacokinetics of Nifedipine Employing Physiologically Based Pharmacokinetic Modeling Approach.
Werdan Romão MA; Pinto L; Cavalli RC; Duarte G; de Moraes NV; Abduljalil K; Moreira FL
J Clin Pharmacol; 2024 May; 64(5):568-577. PubMed ID: 38305718
[TBL] [Abstract][Full Text] [Related]
6. Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.
Balhara A; Kumar AR; Unadkat JD
J Clin Pharmacol; 2022 Sep; 62 Suppl 1(Suppl 1):S94-S114. PubMed ID: 36106781
[TBL] [Abstract][Full Text] [Related]
7. Forecasting Fetal Buprenorphine Exposure through Maternal-Fetal Physiologically Based Pharmacokinetic Modeling.
van Hoogdalem MW; Tanaka R; Abduljalil K; Johnson TN; Wexelblatt SL; Akinbi HT; Vinks AA; Mizuno T
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543269
[TBL] [Abstract][Full Text] [Related]
8. Development of a Generic Fetal Physiologically Based Pharmacokinetic Model and Prediction of Human Maternal and Fetal Organ Concentrations of Cefuroxime.
Liu XI; Green DJ; van den Anker J; Ahmadzia HK; Burckart GJ; Dallmann A
Clin Pharmacokinet; 2024 Jan; 63(1):69-78. PubMed ID: 37962827
[TBL] [Abstract][Full Text] [Related]
9. Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy.
Salem F; Nguyen D; Bush M; Moore KP; Mudunuru J; Stamatopoulos K; Thakkar N; Taskar KS
CPT Pharmacometrics Syst Pharmacol; 2024 May; ():. PubMed ID: 38690782
[TBL] [Abstract][Full Text] [Related]
10. PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Metabolism in Pregnant Subjects and Fetuses.
Le Merdy M; Szeto KX; Perrier J; Bolger MB; Lukacova V
Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38258106
[TBL] [Abstract][Full Text] [Related]
11. Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics.
Yang X; Grimstein M; Pressly M; Fletcher EP; Shord S; Leong R
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140068
[TBL] [Abstract][Full Text] [Related]
12. Total and Free Blood and Plasma Concentration Changes in Pregnancy for Medicines Highly Bound to Plasma Proteins: Application of Physiologically Based Pharmacokinetic Modelling to Understand the Impact on Efficacy.
Coppola P; Butler A; Cole S; Kerwash E
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896215
[TBL] [Abstract][Full Text] [Related]
13. Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders.
Dreier JW; Bjørk MH; Alvestad S; Gissler M; Igland J; Leinonen MK; Sun Y; Zoega H; Cohen JM; Furu K; Tomson T; Christensen J
JAMA Neurol; 2023 Jun; 80(6):568-577. PubMed ID: 37067807
[TBL] [Abstract][Full Text] [Related]
14. Application of PBPK modeling in predicting maternal and fetal pharmacokinetics of levetiracetam during pregnancy.
Chen J; You X; Wu W; Guo G; Lin R; Ke M; Huang P; Lin C
Eur J Pharm Sci; 2023 Feb; 181():106349. PubMed ID: 36496167
[TBL] [Abstract][Full Text] [Related]
15. Association of oxcarbazepine concentration with seizure frequency in pregnant women with epilepsy.
Wei LY; Xu ZY; Lai ZZ; Dong N; Sang YW; Guo Y
Epilepsy Behav Rep; 2024; 25():100640. PubMed ID: 38235017
[TBL] [Abstract][Full Text] [Related]
16. Application of Physiologically Based Pharmacokinetic Modeling to Predict Maternal Pharmacokinetics and Fetal Exposure to Oxcarbazepine.
He L; Ke M; Wu W; Chen J; Guo G; Lin R; Huang P; Lin C
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365185
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.
Liu XI; Momper JD; Rakhmanina N; van den Anker JN; Green DJ; Burckart GJ; Best BM; Mirochnick M; Capparelli EV; Dallmann A
J Clin Pharmacol; 2020 Feb; 60(2):240-255. PubMed ID: 31489678
[TBL] [Abstract][Full Text] [Related]
18. Physiologically based pharmacokinetic modeling to predict maternal pharmacokinetics and fetal carbamazepine exposure during pregnancy.
Chen Y; Ke M; Fang W; Jiang Y; Lin R; Wu W; Huang P; Lin C
Eur J Pharm Sci; 2024 Mar; 194():106707. PubMed ID: 38244810
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
